Drug intelligence / Profile preview

polyphyllin VII

Development stage
Preclinical
Modality
Classical Binding Small Molecules → Small Molecules
01

Overview

Polyphyllin VII is a steroidal saponin and small molecule natural product extracted from the traditional Chinese medicinal herb Paris polyphylla. It exhibits strong anticancer activity against various carcinomas including lung cancer, breast cancer, prostate cancer, endometrial carcinoma, colon cancer (especially CD44-positive cells), and multiple myeloma. Mechanistically, polyphyllin VII induces autophagic cell death by activating the JNK pathway and inhibiting the PI3K/AKT/mTOR pathway. It also acts as an inhibitor of moesin—a regulator of the Wnt/β-catenin pathway—leading to its degradation via the ubiquitin-proteasome system and suppression of Wnt signaling. Additionally, it can upregulate miR‑33a‑5p to enhance sensitivity to hormone therapies in resistant endometrial carcinoma cells. These actions result in reduced cell viability, increased apoptosis or autophagy in tumor cells, inhibition of migration and sphere formation (stemness), overcoming drug resistance (e.g., bortezomib resistance in myeloma), and downregulation of stemness markers such as CD44[2][3][4][5][7][10].

Other names
Polyphyllin Ⅶβ-D-Glucopyranoside, (3β,22α,25R)-26-(β-D-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-α-L-arabinofuranosyl-(1→4)-O-[6-deoxy-α-L-mannopyranosyl-(1→3)]-
02

Targets

JNK (Mitogen-activated protein kinase kinase kinase family)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)CD44 (CD44 antigen)AKT (RAC-alpha serine/threonine-protein kinase)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on polyphyllin VII.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polyphyllin VII.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call